Research and Support Services at NCI-Frederick

1
Research and Support Services at NCI-Frederick

• Charmaine Richman, Ph.D.
• Scientific Administrator
• SAIC-Frederick, Inc.

2
NCI-Frederick

• Federal Funded Research and Development Center
• Government-Owned Contactor-operated facility
• Contractor is currently SAIC-Frederick, Inc.
• Operations and Technical support contract

3
Services and Support

• biopharmaceutical development program
• a high-performance IT center dedicated to
  biomedical research and informatics
• advanced technology programs
• genomics
• proteomics
• imaging
• nanotechnology
• histopathology
• molecular biology
• clinical trial laboratory services

4
Example Peptide Synthesis

• Peptides synthesized on a Beckman Biomek FX
  liquid-handling robot
• Synthesis on porous beads in filter bottom
  microtiter plates
• Typical yield 1uM or 1mg of an 18-mer peptide
• Typically over 90 of peptides are over 90
  pure (i.e. over 90 of mass migrates as a
  single peak when analyzed by mass spec)
• Cost per peptide less than 15.00

5
(No Transcript)
6
Process

• This a cost recover effort
• initially requester discusses a project with the
  appropriate SAIC-Frederick scientist
• A cost estimate will be provided that includes
  the cost plus overhead (no profit)
• Requester accepts cost estimate or not
• NCI reviews request and approves or disapproves
  the work

7
Government Agencies

• SAIC-Frederick services and support are available
  under the Economy Act
• Other government agencies enter into inter-agency
  agreements to facilitate the transfer of
  allocated funds
• NCI-Frederick currently has Interagency
  Agreements with the following Agencies
• USAMRIID
• USAMRMC
• USAG
• USDA
• FDA

8
Point of Contact for Interagency Agreements

• Patty White
• Contract Specialist
• NCI-Frederick
• [phone]
• whitep_at_ncifcrf.gov

9
Work for Others

• WFO is defined as services provided to
  non-Federal Government entitie(s) by an FFRDC
• WFO authority provided in FAR 35.017-3 Using an
  FFRDC
• Services provided must be unique and not compete
  with the private sector (FAR 35.017)
• Services in support of primary sponsor take
  precedence over WFO requests

10
WFO

• SAIC-F services available to perform WFO are made
  available if there is sufficient capacity to
  accommodate the request while still meeting
  Government demands for service
• WFO is not conducted under a subcontract
  therefore federal flow-down contract provisions
  do not apply
• Services performed under WFO are not anticipated
  to involve research, development, or
  demonstration, i.e., services

11
WFO

• WFO services are not collaborations no potential
  IP development anticipated
• If IP is developed under the WFO Agreement, such
  IP will be governed by the IP provisions of the
  SAIC-F OTS Prime Contract

12
Point of Contact for Work for Others

• Carl Garland, PhD
• Administrative Director
• Research Technology Program
• SAIC-Frederick, Inc.
• 301-846-5425
• garland_at_ncifcrf.gov

13
Examples of Projects
14
300K Cancer Gene Sequencing Microarray

• Sequences all exons, splice sites, and promoters
  in all 90 genes known to be mutated in cancer
• Sequences 300kb of target DNA
• Developed in collaboration with Affymetrix

15
Virus Microarray

• Designed to identify and detect all known
  mammalian and avian pathogenic viruses
• Detects both viral RNA and DNA
• 10,000 features (10-20 features per virus)
• Over 600 viruses represented
• Human and avian flu viruses represented as tiling
  paths
• Also designed for detection of new viruses that
  may arise via recombination
• Detection limit 20 virus particles
• Array quality
•         cv less than 4
•         Over 98 reproducibility of detection

16
miRNA Microarray

• 1500 features
• cv less than 5
• All known (confirmed and putative) human, rodent,
  drosophila, C. elegans, zebra fish, xenopus,
  chicken, and arabidposis miRNAs
• Content and architecture under continuing
  development
• Ongoing miRNA discovery efforts for both human
  and mouse

17
Monoclonal Antibody Microarray

• Over 1200 monoclonal antibodies
• cv less than 5
• All antibodies validated by Western
• Ongoing effort to validate all antibodies by mass
  spec
• Dual color labeling
• Direct labeling of protein samples